{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:44:18Z","timestamp":1692711858714},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,5]]},"DOI":"10.4103\/0366-6999.186641","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T10:49:43Z","timestamp":1469011783000},"page":"1778-1783","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations"],"prefix":"10.1097","volume":"129","author":[{"given":"Chao","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Jian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210129","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"R2-3-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"R3-3-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"R9-3-20210129","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/10428190802035966","article-title":"MPL W515L mutation in Chinese patients with myeloproliferative diseases","volume":"49","author":"Xu","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R11-3-20210129","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","article-title":"Thrombotic disease in the myeloproliferative neoplasms","volume":"2012","author":"Falanga","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.23417","article-title":"Polycythemia vera and essential thrombocythemia:2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"Tefferi","year":"2013","journal-title":"Am J Hematol"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"27266","DOI":"10.1074\/jbc.M111.258467","article-title":"Structural and functional relationships between the lectin and arm domains of calreticulin","volume":"286","author":"Pocanschi","year":"2011","journal-title":"J Biol Chem"},{"key":"R16-3-20210129","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BJ20081847","article-title":"Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum","volume":"417","author":"Michalak","year":"2009","journal-title":"Biochem J"},{"key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2353\/ajpath.2008.071027","article-title":"Calreticulin enhances porcine wound repair by diverse biological effects","volume":"173","author":"Nanney","year":"2008","journal-title":"Am J Pathol"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1038\/cddis.2010.82","article-title":"Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia","volume":"1","author":"Wemeau","year":"2010","journal-title":"Cell Death Dis"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1582-4934.2009.00870.x","article-title":"Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia","volume":"14","author":"Schardt","year":"2010","journal-title":"J Cell Mol Med"},{"key":"R20-3-20210129","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2013.382","article-title":"Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis","volume":"28","author":"Chi","year":"2014","journal-title":"Leukemia"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2010.5","article-title":"Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: A population-based study of 311 patients","volume":"24","author":"Girodon","year":"2010","journal-title":"Leukemia"},{"key":"R26-3-20210129","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","article-title":"Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: A retrospective study","volume":"90","author":"Palandri","year":"2011","journal-title":"Ann Hematol"},{"key":"R27-3-20210129","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"Aprognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: A study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"R28-3-20210129","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"R29-3-20210129","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"R30-3-20210129","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"R31-3-20210129","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"R32-3-20210129","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia"},{"key":"R34-3-20210129","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"key":"R35-3-20210129","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.186641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:40:09Z","timestamp":1623958809000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201608050-00003"}},"subtitle":["A Chinese Cohort Clinical Study"],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":35,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.186641","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8,5]]}}}